Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI; Drug · Other
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina

Conditions: Cerebral Palsy Infantile, Disabilities Multiple, Pain
Interventions: PediQUEST ResPOND; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Year and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
Interventions: Placebo, BYM338; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Torrance, California • Savannah, Georgia • Normal, Illinois + 2 more

Conditions: Pleural Mesothelioma, Non-small Cell Lung Cancer
Interventions: THOR-707, Pembrolizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Bacterial Infections, Skin Structures and Soft Tissue Infections
Interventions: Omadacycline, Linezolid; Drug
Lead sponsor: Paratek Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 18
States / cities: Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more

Conditions: Osteoarthritis
Interventions: Customized patient instruments, Traditional Metal Instruments; Device
Lead sponsor: Medacta USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Marrero, Louisiana • Billings, Montana • Meadville, Pennsylvania + 2 more

Conditions: Type 2 Diabetes
Interventions: Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham); Device
Lead sponsor: Fractyl Health Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 51
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 39 more

Conditions: Alzheimer's Disease
Interventions: PF-04360365 0.1 mg/kg, PF-04360365 0.5 mg/kg, PF-04360365 1 mg/kg, Placebo, PF-04360365 3 mg/kg, PF-04360365 8.5 mg/kg; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 15
States / cities: Peoria, Arizona • Phoenix, Arizona • Miami, Florida + 6 more

Conditions: Graft-versus-Host Disease, Immune System Disorders
Interventions: Mycophenolate Mofetil, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Duarte, California • La Jolla, California • Stanford, California + 28 more

Conditions: Breast Cancer
Interventions: Quality-of-life Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Leukemia, Myelodysplasia
Interventions: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 1 Year to 65 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 28
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 22 more

Conditions: Carcinoma, Renal Cell
Interventions: Recombinant Human Lactoferrin; Drug
Lead sponsor: Agennix; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 2 more

Conditions: Diabetes Mellitus, Type 1
Interventions: TOL-3021, TOL-3021 Placebo; Biological · Other
Lead sponsor: Tolerion, Inc.; Industry
Eligibility: 12 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Non-melanoma Skin Cancer
Interventions: Xoft eBx; Device
Lead sponsor: Xoft, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Campbell, California • San Diego, California

Conditions: Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003, PT001, PT005, Tiotropium inhalation powder; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 19
States / cities: Glendale, Arizona • Rancho Mirage, California • Waterbury, Connecticut + 14 more

Conditions: Atherosclerotic Lesions in the Aortorenal Ostium
Interventions: Express™ Renal Premounted Stent System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 14
States / cities: Sarasota, Florida • Peoria, Illinois • Springfield, Illinois + 10 more

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more

Conditions: Metastatic Colorectal Cancer
Interventions: Sym004, FOLFIRI; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 2 more

Conditions: Von Hippel-Lindau Syndrome
Interventions: Dovitinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphedema, Lymphedema of Leg, Chronic Venous Insufficiency, Venous Insufficiency, Lymphedema, Lower Limb
Interventions: Cross over Device (PCD or Dayspring - alternate to first group); Device
Lead sponsor: Koya Medical, Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Oakland, California

Conditions: Arrhythmias, Cardiac
Interventions: CanGaroo Envelope; Device
Lead sponsor: Elutia Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 23
States / cities: Little Rock, Arkansas • Daytona Beach, Florida • Delray Beach, Florida + 20 more

Conditions: Depression
Interventions: ABP688; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: New York, New York • Pittsburgh, Pennsylvania

Conditions: Health Status Unknown, Elevated PSA
Interventions: Biopsy of Prostate, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, MRI Ultrasound Fusion Guided Biopsy; Procedure · Other · Diagnostic Test
Lead sponsor: University of Southern California; Other
Eligibility: 40 Years and older · Male only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 1 more

Search by objective public record fields.

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

The PediQUEST Response to Pain Of Children With Neurologic Disability Pilot Randomized Controlled Trial

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Single-use Efficiency Instruments With Patient Specific Technique (MyKnee®) Versus Traditional Metal Instruments With Conventional Surgical Technique

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Multi-center MRD Registry for Inflammatory Breast Cancer

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)

Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

A Prospective, Multi-center, Single Arm Study Evaluating the Express™ Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium.

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema

CanGaroo® Registry Study

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA